← Oncology Approval Tracker

FDA DECISION ·

Bizengri

zenocutuzumab-zbco · Partner Therapeutics

FDA approvalNew or expanded indicationBiliary tract cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced, unresectable or metastatic cholangiocarcinoma with an NRG1 fusion and progression on or after systemic therapy.

LAMPGEN ANALYSIS

Why it matters

This extends a targeted bispecific into a rare molecularly defined biliary cancer. FDA evaluated response in a small efficacy population within the eNRGy study.

What research teams should watch

Early molecular testing and access to assays that can identify NRG1 fusions can affect referral. State the study denominator when describing response.

PRIMARY RECORDS

Sources